Renaissance Investment Group LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,963 shares of the company’s stock after selling 598 shares during the period. Renaissance Investment Group LLC’s holdings in Johnson & Johnson were worth $2,789,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently bought and sold shares of JNJ. Harding Loevner LP purchased a new stake in Johnson & Johnson during the second quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the period. IHT Wealth Management LLC lifted its holdings in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the period. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson during the second quarter worth $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new stake in Johnson & Johnson during the second quarter worth $177,000. Institutional investors own 67.21% of the company’s stock.
JNJ has been the subject of several analyst reports. Wells Fargo reiterated an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective for the company in a report on Thursday, January 11th. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, Stifel Nicolaus increased their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $146.26.
Johnson & Johnson stock opened at $133.68 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32. The stock has a market capitalization of $358,650.34, a price-to-earnings ratio of 18.31, a P/E/G ratio of 2.13 and a beta of 0.77.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the prior year, the firm earned $1.58 EPS. The firm’s revenue was up 11.5% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.51%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s payout ratio is 861.54%.
In related news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.19% of the stock is owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.